KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at Jones Trading ...

US-based biopharmaceutical company KalVista Pharmaceuticals has finished enrolling subjects in its KONFIDENT-KID trial of ...

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) have earned an average recommendation of “Buy” from ...

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the completion of enrollment in the open-label KONFIDENT-KID ...

TD Cowen analyst Stacy Ku maintained a Buy rating on KalVista Pharmaceuticals (KALV – Research Report) today and set a price target of $30.00.

In a report released today, Paul Matteis from Stifel Nicolaus reiterated a Buy rating on KalVista Pharmaceuticals (KALV – Research Report), ...

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the completion of enrollment in the open-label KONFIDENT-KID clinical trial of sebetralstat, an investigational, novel, oral plasma ...

On Wednesday, Cantor Fitzgerald maintained an Overweight rating on Kalvista Pharmaceuticals Inc (NASDAQ:KALV), following the company’s recent webinar that focused on its launch strategy for ...

On Wednesday, Cantor Fitzgerald maintained an Overweight rating on Kalvista Pharmaceuticals Inc (NASDAQ:KALV), following the company’s recent webinar that focused on its launch strategy for ...

CAMBRIDGE, Mass. & SALISBURY, England - KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has announced the completion of enrollment for its KONFIDENT-KID clinical trial, which evaluates sebetralstat ...

CAMBRIDGE, Mass. & SALISBURY, England - KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has announced the completion of enrollment for its KONFIDENT-KID clinical trial, which evaluates sebetralstat, a ...

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today released financial results for the third fiscal quarter ended January 31, 2025, and provided an operational update.